The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS).
 
Yukihide Kanemitsu
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Covidien; Covidien; Covidien; Covidien; Ethicon; Ethicon; Ethicon; Ethicon; Intuitive Surgical; Intuitive Surgical; Intuitive Surgical; Intuitive Surgical
Consulting or Advisory Role - Covidien; Covidien; Covidien; Covidien
 
Kohei Shitara
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Novartis; Novartis; Novartis; Novartis; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Takeda; Takeda; Takeda; Takeda
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Junki Mizusawa
No Relationships to Disclose
 
Tetsuya Hamaguchi
Honoraria - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Fujifilm; Fujifilm; Fujifilm; Fujifilm; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Dai Shida
No Relationships to Disclose
 
Koji Komori
No Relationships to Disclose
 
Satoshi Ikeda
No Relationships to Disclose
 
Hitoshi Ojima
No Relationships to Disclose
 
Seiji Hasegawa
No Relationships to Disclose
 
Akio Shiomi
No Relationships to Disclose
 
Jun Watanabe
Honoraria - Covidien; Covidien; Covidien; Covidien; Ethicon; Ethicon; Ethicon; Ethicon
 
Yasumasa Takii
No Relationships to Disclose
 
Takashi Yamaguchi
No Relationships to Disclose
 
Kenji Katsumata
No Relationships to Disclose
 
Masaaki Ito
No Relationships to Disclose
 
Jyunji Okuda
Honoraria - Covidien; Covidien; Covidien; Covidien; Ethicon; Ethicon; Ethicon; Ethicon
 
Ryoji Hyakudomi
No Relationships to Disclose
 
Yasuhiro Shimada
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); MSD K.K (Inst); MSD K.K (Inst); MSD K.K (Inst); MSD K.K (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroshi Katayama
Honoraria - Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical